These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 16953982

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Emerging bone health issues in women with breast cancer in Hawai'i.
    Carney JF, Davis J.
    Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
    Yonehara Y, Iwamoto I, Kosha S, Rai Y, Sagara Y, Douchi T.
    J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prevention of osteoporosis after breast cancer.
    Reid DM.
    Maturitas; 2009 Sep 20; 64(1):4-8. PubMed ID: 19709826
    [Abstract] [Full Text] [Related]

  • 9. Update on aromatase inhibitors in breast cancer.
    Gould RE, Garcia AA.
    Curr Opin Obstet Gynecol; 2006 Feb 20; 18(1):41-6. PubMed ID: 16493259
    [Abstract] [Full Text] [Related]

  • 10. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
    Coleman RE, Body JJ, Gralow JR, Lipton A.
    Cancer Treat Rev; 2008 Feb 20; 34 Suppl 1():S31-42. PubMed ID: 18486346
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Adverse bone effects during pharmacological breast cancer therapy.
    Bjarnason NH, Hitz M, Jorgensen NR, Vestergaard P.
    Acta Oncol; 2008 Feb 20; 47(4):747-54. PubMed ID: 18465344
    [Abstract] [Full Text] [Related]

  • 16. Effects of third-generation aromatase inhibitors on bone.
    McCloskey E.
    Eur J Cancer; 2006 May 20; 42(8):1044-51. PubMed ID: 16554149
    [Abstract] [Full Text] [Related]

  • 17. The effect of aromatase inhibitors on bone metabolism.
    Folkestad L, Bjarnason NH, Bjerregaard JK, Brixen K.
    Basic Clin Pharmacol Toxicol; 2009 Jan 20; 104(1):3-10. PubMed ID: 19152547
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Aromatase inhibitor-associated arthralgia syndrome.
    Burstein HJ.
    Breast; 2007 Jun 20; 16(3):223-34. PubMed ID: 17368903
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.